1 / 33

A Study for development of a new polyherbal preparation for HIV-infected patients

A Study for development of a new polyherbal preparation for HIV-infected patients. Tran Van Hien, Tran Thuy, Jorma Hinkula et al HongKong, 2006. HIV infection in Vietnam The first case was found in 1990 in Ho Chi Minh city. Prevention and treatment of HIV/AIDS are big problems with:

elton
Download Presentation

A Study for development of a new polyherbal preparation for HIV-infected patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A Study for development of a new polyherbal preparation for HIV-infected patients Tran Van Hien, Tran Thuy, Jorma Hinkula et al HongKong, 2006

  2. HIV infection in Vietnam • The first case was found in 1990 in Ho Chi Minh city. • Prevention and treatment of HIV/AIDS are big problems with: • Increasing cases, difficult to control • 42,000 infected cases (12/2001) • 250,000 infected cases (estimated, 2005), 13,000 died • HAART is very expensive 2.53 million VND/month/patient • Others

  3. Treatment of HIVAIDS HIV/AIDS: complicate, multistage not any single therapy can save patient HAART: great achievements in the recent decades, can not affordable in developing countries, side effects with pathological disorders, continuing deficiency of immune system, of nervous system.

  4. Herbal medicines for HIV/AIDS • Anti HIV activity: • Anti HIV replication • HIV enzym, protein intervention • Intervention in virus – cell link • Improving general health status, protection/ promoting immune response • Unfortunately infection • Regulation of oxidative balance

  5. Oxidative stress in HIV infection • Play a role in pathogenic and developing process of HIV infection. • Oxidative stress  antioxidant system. Over production of ROS injures DNA of lymphocytes.

  6. CD4 count: - HIV(+): 394/mm3 - HIV(+)P: 360/mm3 - HIV(+)V: 460/mm3

  7. Lymphocytes are sensitive • Apoptosis is initiated by oxidative stress. A cause of cell loss in HIV/AIDS patients. • Changed bases of DNA  apoptosis. • Herbal medicines: anti HIV + antioxidant, protect lymphocytes.

  8. HTA formulation 4 herbs: tonifying the Blood and the Energy (immunomodulatory activity) 4 herbs: antibacterial, anti HIV Have been used in treatment of immunodeficient cases (cancers after or undergoing radiotherapy, prolong infections).

  9. In mice exposing Cobalt-60 Extract HTA1: water extract Extract HTA2: alcohol extract with some treatments

  10. Fig1. Body weight of mice and spleen on day 8 after radiation exposure (7Gy) a. Intact mice c. HTA1 b. Control d. HTA2

  11. Table 5. Ratio between weight of immune organs/body weight

  12. Fig 2. Phagocytic response Fig 2a. Rate of phagocytes Fig 2b. Phagocytic index

  13. Fig 3. Marrow cell counts in mice on day 8 after Cobalt – 60 exposure

  14. Fig 4. Rate of antibody producting splenocytes in mice on day 8 after Cobalt -60 exposure

  15. Protective effects of HTA2 on blood peripheral lymphocyte against H2O2 – induced injury 20 samples from healthy people Protocol a: cell toxification by 10-8M H2O2 +H2O2 wash +/- PHA +/- HTA + Thymindin Lymphocytes Cells Cell measurement (Scincilator) (Packard) Protocol b: recovering effect

  16. Protective Effects by HTA2

  17. Antiperoxydative effects in brain homogenates g/ml

  18. Antiperoxydative effects in liver homogenates g/ml

  19. Inhibitory effects in O-2 production g/ml

  20. Safety of HTA product * Acute toxicity: 5 – 45 g/kg body weight/day Subchronic toxicity: 500mg/kg/day 2000mg/kg/day 8 weeks • Biochemical, Hematological indices • Histological examinations

  21. A clinical study HIV infected, who received the drugs voluntarily Control group: 17 Study group: 21 (20 males, 1 female Ages: 21-30 yrs in 52% (17 – 48 yrs old) Infection:  5 year   10 year Infection route: drug addiction occupied 68,4% T.CD4  500 cells/mm3

  22. Weight at 0,3 and 6 month exam

  23. Karnofsky score at 3 and 6 month exam

  24. Clinical classification CDC – 1993 at 3 and 6 month exam

  25. T-CD4 counts (cells/mm3)

  26. T-CD8 counts (cells/mm3)

  27. Average T-CD4/T-CD8

  28. Others BRC: change was not significant increased in the study group P < 0.05 at the 6 month cooperation between 2 groups ALS, AST: no change Protective effect in T-CD4 : better in group with TCD4 > 200 cells/mm3.

  29. Samples were tested in vitro against 2 Lab HIV – 1 strains (HIV-1 III3and SF2 in Jurkat T cells and in hu PHA/IL-2 activated PBMC) >80% toxicity Frations HIV-1 IIIB cells hu PBMC Jurkal cell line F3 30 – 60 g/ml 20 – 60 g/ml F6 60 – 120 g/ml 125 – 250 g/ml

More Related